TrialGynecologic oncology2014

A phase II evaluation of nintedanib (BIBF-1120) in the treatment of recurrent or persistent endometrial cancer: an NRG Oncology/Gynecologic Oncology Group Study.

Don S Dizon et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.